STOCK TITAN

Prosight group discloses 4% MeiraGTx (NASDAQ: MGTX) ownership stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

MeiraGTx Holdings plc received an updated ownership report from a Prosight investment group on Ordinary Shares. The group, including Prosight Management, Prosight Fund, Prosight Plus Fund, Prosight Partners and W. Lawrence Hawkins, reports beneficial ownership of 3,211,788 Ordinary Shares, or 4.0% of the company, as of the event date. This percentage is calculated using 80,490,889 Ordinary Shares outstanding as of October 28, 2025. The reporting persons certify the shares are not held to change or influence control of MeiraGTx and are reported on a passive Schedule 13G/A basis.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 80,490,889 Ordinary Shares, $0.00003881 par value per share ("Ordinary Shares") of MeiraGTx Holdings plc (the "Issuer") outstanding as of October 28, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 80,490,889 Ordinary Shares of the Issuer outstanding as of October 28, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 80,490,889 Ordinary Shares of the Issuer outstanding as of October 28, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 80,490,889 Ordinary Shares of the Issuer outstanding as of October 28, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 80,490,889 Ordinary Shares of the Issuer outstanding as of October 28, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 13, 2025.


SCHEDULE 13G



Prosight Management, LP
Signature:Prosight Partners, LLC
Name/Title:General Partner
Date:02/13/2026
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner
Date:02/13/2026
Prosight Fund, LP
Signature:Prosight Management, LP
Name/Title:General Partner
Date:02/13/2026
Signature:Prosight Partners, LLC
Name/Title:Sole Manager of the General Partner
Date:02/13/2026
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner of the General Partner
Date:02/13/2026
Prosight Plus Fund, LP
Signature:Prosight Management, LP
Name/Title:General Partner
Date:02/13/2026
Signature:Prosight Partners, LLC
Name/Title:General Partner of the General Partner
Date:02/13/2026
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner of the General Partner
Date:02/13/2026
Prosight Partners, LLC
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager
Date:02/13/2026
W. Lawrence Hawkins
Signature:/s/ W. Lawrence Hawkins
Name/Title:W. Lawrence Hawkins
Date:02/13/2026
Exhibit Information

Joint Filing Agreement (incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on May 15, 2023, by the Reporting Persons with the SEC).

FAQ

What MeiraGTx (MGTX) ownership does the Prosight group report in this Schedule 13G/A?

The Prosight group reports beneficial ownership of 3,211,788 MeiraGTx Ordinary Shares, representing 4.0% of the class. This is based on 80,490,889 Ordinary Shares outstanding as of October 28, 2025, as disclosed in MeiraGTx’s Form 10-Q.

Who are the reporting persons in the MeiraGTx (MGTX) Schedule 13G/A filing?

The filing is jointly made by Prosight Management, LP, Prosight Fund, LP, Prosight Plus Fund, LP, Prosight Partners, LLC, and W. Lawrence Hawkins. The entities outline their control relationships and note that various parties may be deemed to beneficially own the same MeiraGTx securities.

How much of MeiraGTx (MGTX) stock does W. Lawrence Hawkins report owning?

W. Lawrence Hawkins reports beneficial ownership of 3,211,788 MeiraGTx Ordinary Shares, including 2,000 shares with sole voting and dispositive power. The remainder is held with shared voting and dispositive power through related Prosight entities and managed accounts outlined in the filing.

Is the Prosight group’s MeiraGTx (MGTX) stake above or below 5%?

The Prosight group’s stake is below 5%, at 4.0% of MeiraGTx’s Ordinary Shares. The filing’s Item 5 confirms ownership of 5 percent or less of the class, aligning with the aggregate beneficial ownership reported for the group.

What does the MeiraGTx (MGTX) Schedule 13G/A say about control intentions?

The reporting persons certify the MeiraGTx securities were not acquired and are not held to change or influence control of the issuer. They state the holdings are not in connection with any control-seeking transaction, consistent with passive ownership under Schedule 13G rules.

Which Prosight entities directly hold MeiraGTx (MGTX) shares, and in what amounts?

Prosight Fund directly holds 152,317 MeiraGTx Ordinary Shares, and Prosight Plus Fund directly holds 700,205 shares. Additional MeiraGTx shares are held in managed accounts advised by Prosight Management, contributing to the total 3,211,788 shares reported as beneficially owned.
Meiragtx Holdings Plc

NASDAQ:MGTX

MGTX Rankings

MGTX Latest News

MGTX Latest SEC Filings

MGTX Stock Data

592.41M
53.50M
24.15%
64.97%
4.35%
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
NEW YORK